This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.
PRIMARY OBJECTIVES: I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT. II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and correlate them with objective response parameters such as Response Assessment in Neuro-Oncology (RANO) and survival. OUTLINE: Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
7
Undergo FDG PET/CT
Undergo FDG PET/CT
Undergo FDG PET/CT
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Changes in glucose uptake
Standardized uptake values (SUV) will be calculated for different organs and for regions of tumor. Further, regional target to background count-activity ratios will be established.
Time frame: From baseline up to 48 hours
Very early changes in tumor glucose uptake predictive for objective treatments response and survival assessed using RANO criteria
SUV will be calculated for different organs and for regions of tumor. Further, regional target to background count-activity ratios will be established.
Time frame: One PET/CT 48 hours after start of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.